Disease · EFO_1001480
metastatic colorectal cancer
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. metastatic colorectal cancer. Diseases, record EFO_1001480. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001480
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- metastatic colorectal cancer
- Open Targets ID
- EFO_1001480
- Highest stage of its drugs
- Approval, for 3 of its 80 drugs, from TTD
Source Open Targets
Drugs80
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Approval | TTD | 29 | 26 | 26 | Drugs and targets |
| REGORAFENIB | CHEMBL1946170 | Small molecule | Approval | TTD | 10 | 9 | 9 | Drugs and targets |
| AFLIBERCEPT | CHEMBL1742982 | Protein | Approval | TTD | 2 | 1 | 1 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 36 | 36 | 29 | Drugs and targets |
| IRINOTECAN | CHEMBL481 | Small molecule | Phase 3 | ClinicalTrials.gov | 35 | 34 | 30 | Drugs and targets |
| CETUXIMAB | CHEMBL1201577 | Antibody | Phase 3 | ClinicalTrials.gov | 26 | 26 | 26 | Drugs and targets |
| OXALIPLATIN | CHEMBL414804 | Small molecule | Phase 3 | ClinicalTrials.gov | 26 | 26 | 25 | Drugs and targets |
| LEUCOVORIN | CHEMBL1679 | Small molecule | Phase 3 | ClinicalTrials.gov | 19 | 19 | 15 | Drugs and targets |
| PANITUMUMAB | CHEMBL1201827 | Antibody | Phase 3 | ClinicalTrials.gov | 13 | 13 | 13 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 10 | Drugs and targets |
1 to 10 of 80
See all 80 drugsTargets80
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PDCD1 | Programmed cell death protein 1 | 9 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| EGFR | Epidermal growth factor receptor | 6 | Epidermal growth factor receptor erbB1 antagonist; Epidermal growth factor receptor erbB1 inhibitor | Phase 3 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 6 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 6 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/2324 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 6 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/3791 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 4 | Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other | Phase 3 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 4 | Stem cell growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 4 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/5159 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 3 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Approval | https://conductscience.org/library/genes/25 | Drugs and targets |
| BRAF | Serine/threonine-protein kinase B-raf | 3 | Serine/threonine-protein kinase B-raf inhibitor | Approval | https://conductscience.org/library/genes/673 | Drugs and targets |
1 to 10 of 80
See all 80 targetsTrials101
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00339183 | Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone | Phase 3 | 1,186 | 2014-05-06 | Metastatic Colorectal Cancer | FLUOROURACIL, IRINOTECAN, LEUCOVORIN, PANITUMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Phase 2 | 1,044 | 2020-07-24 | Colorectal Cancer | ATEZOLIZUMAB, CAPECITABINE, CETUXIMAB, COBIMETINIB, FLUOROURACIL, PERTUZUMAB, TRASTUZUMAB, VEMURAFENIB | Its record names the disease | ClinicalTrials.gov |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Phase 3 | 702 | 2020-07-14 | BRAF V600E-mutant Metastatic Colorectal Cancer | BINIMETINIB, CETUXIMAB, ENCORAFENIB | Its record names the disease | ClinicalTrials.gov |
| NCT02091141 | My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | Phase 2 | 673 | 2024-07-23 | Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer | ALECTINIB, ATEZOLIZUMAB, COBIMETINIB, ERLOTINIB, PERTUZUMAB, TRASTUZUMAB, VEMURAFENIB, VISMODEGIB | Its record names the disease | ClinicalTrials.gov |
| NCT02720068 | Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) | Phase 1 | 481 | 2025-05-30 | Neoplasms | FAVEZELIMAB, FLUOROURACIL, IRINOTECAN, LENVATINIB, LEUCOVORIN, OXALIPLATIN, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00418938 | SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial | Phase 2 | 266 | 2014-03-28 | Cancer, Colon Cancer, Colorectal Cancer, Metastatic Cancer, Rectal Cancer, Metastatic Colorectal Cancer | BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN CALCIUM, PANITUMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03374254 | Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651) | Phase 1 | 116 | 2024-10-15 | Metastatic Colorectal Cancer | BINIMETINIB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03519412 | Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status | Phase 2 | 107 | 2026-03-03 | Colorectal Neoplasms, Microsatellite Instability | PEMBROLIZUMAB, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03271047 | Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation | Phase 2 | 75 | 2021-11-02 | MSS, RAS-mutant Colorectal Cancer | BINIMETINIB, IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02963831 | A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Phase 1/2 | 67 | 2022-12-22 | Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer | DURVALUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 101
See all 101 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Panitumumab Plus FOLFIRI vs FOLFIRI Alone: serious adverse events | 232 of 587 | 175 of 594 | 1,181 | NCT00339183 | Trial comparisons |
| Panitumumab Plus FOLFIRI vs Bevacizumab Plus FOLFIRI: serious adverse events | 61 of 133 | 39 of 131 | 264 | NCT00418938 | Trial comparisons |
| MMR-proficient (MMRp) vs MMR-deficient (MMRd)/TMZ-primed TMB-high MMR-proficient (MMRp): deaths from any cause | 6 of 66 | 13 of 57 | 123 | NCT03519412 | Trial comparisons |
| MMR-proficient (MMRp) vs MMR-deficient (MMRd)/TMZ-primed TMB-high MMR-proficient (MMRp): serious adverse events | 14 of 66 | 20 of 57 | 123 | NCT03519412 | Trial comparisons |
| Study Arm - VOR With HCQ vs Control Arm - Regorafenib: deaths from any cause | 20 of 20 | 22 of 22 | 42 | NCT02316340 | Trial comparisons |
| Study Arm - VOR With HCQ vs Control Arm - Regorafenib: serious adverse events | 0 of 20 | 0 of 22 | 42 | NCT02316340 | Trial comparisons |
| Phase 1b: Nivolumab+Binimetinib vs Phase 1b: Nivolumab+Ipilimumab+Binimetinib: Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) | 1 of 9 | 2 of 11 | 20 | NCT03271047 | Trial comparisons |
| Cohort 1 - Pre-operative Escalation Doses of MVT-5873 (HuMab-5B1) vs Cohort 2 - Pre-operative Recommended Dose (RD) of MVT-5873 (HuMab-5B1): Number of Participants With Disease Recurrence At 1 Year | 2 of 8 | 0 of 1 | 9 | NCT03801915 | Trial comparisons |
Cohort 1 - Pre-operative Escalation Doses of MVT-5873 (HuMab-5B1) vs Cohort 2 - Pre-operative Recommended Dose (RD) of MVT-5873 (HuMab-5B1): Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 7 of 8 | 1 of 1 | 9 | NCT03801915 | Trial comparisons |
| Cohort 1 - Pre-operative Escalation Doses of MVT-5873 (HuMab-5B1) vs Cohort 2 - Pre-operative Recommended Dose (RD) of MVT-5873 (HuMab-5B1): deaths from any cause | 1 of 8 | 0 of 1 | 9 | NCT03801915 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials108
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_1001480
GET https://conductscience.org/api/diseases/v1/EFO_1001480/drugs?page=2